ACTRN12615000216516
Recruiting
N/A
An audit of the impact of a change in the blood glucose targets protocol on intensive care mortality for diabetic patients admitted to the intensive care unit
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Diabetes
- Sponsor
- Austin Health
- Enrollment
- 700
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult patients admitted to the intensive care unit with a medical diagnosis of diabetes
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Changes of flow in Arterial anastomosis of Free flap after the Intraoperative administration of AlprostadilDiseases of the skin and subcutaneous tissueKCT0002166Asan Medical Center44
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-DEBayer HealthCare AG18
Active, Not Recruiting
N/A
An interaction study to evaluate changes in blood pressure following 1, 1.5, 2, and 2.5 mg riociguat tid (dose titration) compared to placebo treatment on the background of stable sildenafil pretreatment in subjects with symptomatic pulmonary arterial hypertension - PATENT PLUSPulmonary arterial hypertension.MedDRA version: 9.1Level: LLTClassification code 10064911EUCTR2010-018863-40-ITBayer Health Care AG36
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.1Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-CZBayer HealthCare AG36
Active, Not Recruiting
N/A
Evaluation of the pharmacodynamic effect of the combination of Sildenafil and Riociguat on blood pressure and other safety parametersPulmonary arterial hypertensionMedDRA version: 14.0Level: PTClassification code 10064911Term: Pulmonary arterial hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2010-018863-40-PLBayer HealthCare AG36